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Purpose of the study
Interference of clinical laboratory assays by endogenous
and exogenous substances in the blood is well known. To
date, there are no clear guidelines on the testing of hemo-
lyzed plasma in clinical laboratories. A conservative
approach of alerting the physician with re-sampling is
advised. This study focuses on the effect of processed
(2006/2007), hemolyzed (in vivo/in vitro) plasma (visual
inspection) on genotyping (virco®TYPE HIV 1) and phe-
notyping (Antivirogram®) success at Virco.
Methods
The viral RNA extraction kits (QiaAmp Virus MDx kit:
965652 or Easymag Nuclisens: 280130–280135) are
highly sensitive in deriving intact, good quality RNA from
hemolyzed or non-hemolyzed plasma, leading to success-
ful amplification of PR-RT genes. The validity of the
obtained result was confirmed by comparing the results
from previous or subsequent visits/services from the same
patient, where available.
Summary of results
In 2006, 315 hemolyzed samples arrived at Virco. From
the 263 genotype requests, 246 were successfully geno-
typed (positive) and for 17 no genotype was obtained
(negative, four samples with VL <1000 cp/ml, eight
unknown VL, and three with VL >1000 cp/ml). From the
78 phenotype requests, 72 were positive and six negative
(three with VL unknown and three with VL >1000 cp/ml).
In 2007, 277 hemolyzed samples arrived at Virco. From
the 210 genotype requests, 197 were positive and 13 neg-
ative (one with VL <1000 cp/ml, seven unknown VL, and
five with VL >1000 cp/ml). From the 49 phenotype
requests, 43 were positive and six negative (three with VL
unknown and three with VL >1000 cp/ml). No limitations
were observed for the different Clades.
Conclusion
The success rate for hemolyzed samples with VL >1000
cp/ml was >97% for both years and is similar to the suc-
cess rate for non-hemolyzed samples with VL >1000 cp/
ml (>98% for 2006 and >97% for 2007), indicating that
hemolyzed samples can be processed for resistance testing
under circumstances where re-sampling is difficult. The
sensitivity to phenotyping clearly demonstrates the integ-
rity of the amplified product that can be used to generate
viable recombinant virus stocks. Further investigation is
required on the severity of hemolysis and detection of
well-defined mixtures within hemolyzed samples.
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